Humira with 2022 global revenue of approximately $21.2 billion was the highest-revenue drug in pharmaceutical history, and its patent cliff set the commercial template for how PBMs will handle the next generation of biologic LOEs
La eleccin entre semaglutida oral e inyectable debe individualizarse segn mltiples factores clnicos, preferencias personales y objetivos teraputicos
All controlled-access clinical trial datasets provided by Dr
We need to better educate the public because how this drug behaves in our body and its long-term safety are not yet fully understood. The errors driving the spike in calls to poison control centers were, in many cases, preventable
Novo Nordisk) for the treatment of type 2 diabetes and obesity, it is not surprising that patients taking a semaglutide when examined by an eye care professional also have one or more ocular diseases
Novo Nordisk called it deceptive mass sales under a personalization guise